Published in J Med Chem on April 09, 2009
Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem (2010) 0.93
Dirhodium-catalyzed C-H arene amination using hydroxylamines. Science (2016) 0.88
Development of a new class of aromatase inhibitors: design, synthesis and inhibitory activity of 3-phenylchroman-4-one (isoflavanone) derivatives. Bioorg Med Chem (2012) 0.87
Indolequinone inhibitors of NRH:quinone oxidoreductase 2. Characterization of the mechanism of inhibition in both cell-free and cellular systems. Biochemistry (2011) 0.81
Natural compounds with aromatase inhibitory activity: an update. Planta Med (2010) 0.81
Screening natural products for inhibitors of quinone reductase-2 using ultrafiltration LC-MS. Anal Chem (2010) 0.81
Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective. J Med Chem (2016) 0.78
X-ray structural studies of quinone reductase 2 nanomolar range inhibitors. Protein Sci (2011) 0.78
Design, synthesis, and biological evaluation of potent quinoline and pyrroloquinoline ammosamide analogues as inhibitors of quinone reductase 2. J Med Chem (2011) 0.78
Lignin-derived oak phenolics: a theoretical examination of additional potential health benefits of red wine. J Mol Model (2010) 0.76
Spongiapyridine and related spongians isolated from an Indonesian Spongia sp. J Nat Prod (2014) 0.76
Investigation of fluorinated and bifunctionalized 3-phenylchroman-4-one (isoflavanone) aromatase inhibitors. Bioorg Med Chem (2013) 0.75
An efficient method for the construction of polysubstituted 4-pyridones via self-condensation of β-keto amides mediated by P2O5 and catalyzed by zinc bromide. Beilstein J Org Chem (2013) 0.75
Bioactive compounds from the fern Lepisorus contortus. J Nat Prod (2011) 0.75
Neoflavonoids and tetrahydroquinolones as possible cancer chemopreventive agents. Chem Biol Drug Des (2012) 0.75
The Protein Data Bank. Nucleic Acids Res (2000) 187.10
New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst (1990) 23.46
Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry (2004) 1.59
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta. J Nat Prod (1993) 1.56
Crystal structure of human quinone reductase type 2, a metalloflavoprotein. Biochemistry (1999) 1.34
Human NAD(P)H:quinone oxidoreductase2. Gene structure, activity, and tissue-specific expression. J Biol Chem (1994) 1.33
NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem Pharmacol (2005) 1.19
Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. Cancer Res (2000) 1.18
Molecular tools to study melatonin pathways and actions. Trends Pharmacol Sci (2005) 1.18
An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem Biophys Res Commun (2001) 1.17
Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2. Biochem J (2008) 1.13
Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J Med Chem (2004) 1.10
NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. Biochem Pharmacol (2006) 1.09
Synthesis and biological evaluation of (+/-)-abyssinone II and its analogues as aromatase inhibitors for chemoprevention of breast cancer. J Med Chem (2007) 1.07
Quinone reductase 2 is a catechol quinone reductase. J Biol Chem (2008) 0.96
Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor. Br J Cancer (2006) 0.95
Crystal structure of quinone reductase 2 in complex with cancer prodrug CB1954. Biochem Biophys Res Commun (2005) 0.95
Quinone reductase 2 substrate specificity and inhibition pharmacology. Chem Biol Interact (2005) 0.94
Miliusanes, a class of cytotoxic agents from Miliusa sinensis. J Med Chem (2006) 0.91
Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3. FEBS Lett (2004) 0.90
A possible association between an insertion/deletion polymorphism of the NQO2 gene and schizophrenia. Psychiatr Genet (2003) 0.83
Synthesis of the acridone alkaloids glyfoline and congeners. Structure-activity relationship studies of cytotoxic acridones. J Med Chem (1992) 0.81
Nybomycin. VII. Preparative routes to nybomycin and deoxynybomycin. J Am Chem Soc (1973) 0.80
Nybomycin. IV. Total synthesis of deoxynybomycin. J Am Chem Soc (1970) 0.80
SRS-A antagonist pyranoquinolone alkaloids from east African Fagara plants and their synthesis. Bioorg Med Chem (1996) 0.79
Nybomycin. 9. Synthetic and biosynthetic incorporation of 15N as a means of assigning the 13C nuclear magnetic resonance spectrum of nybomycin 1,2. J Am Chem Soc (1977) 0.78
Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry (2005) 3.57
Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. Proc Natl Acad Sci U S A (2005) 2.92
The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J Virol (2005) 2.49
Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst (2003) 2.31
Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme. Proc Natl Acad Sci U S A (2006) 2.28
Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res (2007) 2.26
Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem (2005) 2.12
Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst (2005) 2.09
Botanicals in cancer chemoprevention. Cancer Metastasis Rev (2002) 2.09
Cancer prevention with natural compounds. Semin Oncol (2010) 1.98
Cancer chemopreventive activity of resveratrol. Ann N Y Acad Sci (2002) 1.88
New manzamine alkaloids with activity against infectious and tropical parasitic diseases from an Indonesian sponge. J Nat Prod (2003) 1.81
Synthesis and anti-HIV activity of new metabolically stable alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors incorporating N-methoxy imidoyl halide and 1,2,4-oxadiazole systems. J Med Chem (2007) 1.76
What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One (2011) 1.74
New chemical constituents of Euphorbia quinquecostata and absolute configuration assignment by a convenient Mosher ester procedure carried out in NMR tubes. J Nat Prod (2002) 1.74
Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris. J Org Chem (2004) 1.69
Deubiquitinating and interferon antagonism activities of coronavirus papain-like proteases. J Virol (2010) 1.64
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. Mol Cancer Ther (2009) 1.64
Human, rat, and mouse metabolism of resveratrol. Pharm Res (2002) 1.62
Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol (2009) 1.58
Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. J Agric Food Chem (2003) 1.56
Identification of the highly reactive cysteine 151 in the chemopreventive agent-sensor Keap1 protein is method-dependent. Chem Res Toxicol (2007) 1.53
Bioactive 5,6-dihydro-alpha-pyrone derivatives from Hyptis brevipes. J Nat Prod (2009) 1.48
NFkappaB: a promising target for natural products in cancer chemoprevention. Phytother Res (2010) 1.45
Natural inhibitors of carcinogenesis. Planta Med (2004) 1.43
Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem (2010) 1.41
A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A (2008) 1.39
Proteolytic processing and deubiquitinating activity of papain-like proteases of human coronavirus NL63. J Virol (2007) 1.39
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests. J Nat Prod (2002) 1.39
Sites of alkylation of human Keap1 by natural chemoprevention agents. J Am Soc Mass Spectrom (2007) 1.36
A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. Mol Cancer Ther (2006) 1.36
Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol (2006) 1.36
Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol. J Agric Food Chem (2002) 1.36
Molecular mechanisms of natural products in chemoprevention: induction of cytoprotective enzymes by Nrf2. Mol Nutr Food Res (2008) 1.33
Synthesis and anticancer activity of brefeldin A ester derivatives. J Med Chem (2006) 1.32
Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison. Mol Pharmacol (2004) 1.29
Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles. J Med Chem (2006) 1.29
Design, synthesis, and biological evaluation of antiviral agents targeting flavivirus envelope proteins. J Med Chem (2008) 1.28
Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J (2010) 1.26
Metabolic stress, reactive oxygen species, and arrhythmia. J Mol Cell Cardiol (2011) 1.26
Quinone reductase induction as a biomarker for cancer chemoprevention. J Nat Prod (2006) 1.24
Design, synthesis, and biological evaluation of indenoisoquinoline topoisomerase I inhibitors featuring polyamine side chains on the lactam nitrogen. J Med Chem (2003) 1.22
Synthesis of new dihydroindeno[1,2-c]isoquinoline and indenoisoquinolinium chloride topoisomerase I inhibitors having high in vivo anticancer activity in the hollow fiber animal model. J Med Chem (2002) 1.21
Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation. Clin Cancer Res (2003) 1.21
Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings. J Med Chem (2004) 1.20
Xanthohumol isolated from Humulus lupulus Inhibits menadione-induced DNA damage through induction of quinone reductase. Chem Res Toxicol (2005) 1.20
Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity. Mol Nutr Food Res (2011) 1.20
Black cohosh (Cimicifuga racemosa L.) protects against menadione-induced DNA damage through scavenging of reactive oxygen species: bioassay-directed isolation and characterization of active principles. J Agric Food Chem (2002) 1.19
Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids. J Med Chem (2003) 1.19
Total synthesis and biological evaluation of 22-hydroxyacuminatine. J Med Chem (2006) 1.18
Modification of keap1 cysteine residues by sulforaphane. Chem Res Toxicol (2011) 1.17
On the binding of indeno[1,2-c]isoquinolines in the DNA-topoisomerase I cleavage complex. J Med Chem (2005) 1.17
Suppression of TNF-α induced NFκB activity by gallic acid and its semi-synthetic esters: possible role in cancer chemoprevention. Nat Prod Res (2010) 1.17
Structural analysis of a viral ovarian tumor domain protease from the Crimean-Congo hemorrhagic fever virus in complex with covalently bonded ubiquitin. J Virol (2011) 1.16
Design, synthesis, and biological evaluation of cytotoxic 11-aminoalkenylindenoisoquinoline and 11-diaminoalkenylindenoisoquinoline topoisomerase I inhibitors. Bioorg Med Chem (2004) 1.15
"Studies on biodiversity of Vietnam and Laos" 1998-2005: examining the impact. J Nat Prod (2006) 1.14
Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors. J Med Chem (2005) 1.13
Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2. Biochem J (2008) 1.13
Crystal structure of lumazine synthase from Mycobacterium tuberculosis as a target for rational drug design: binding mode of a new class of purinetrione inhibitors. Biochemistry (2005) 1.12
Structure-based and random mutagenesis approaches increase the organophosphate-degrading activity of a phosphotriesterase homologue from Deinococcus radiodurans. J Mol Biol (2009) 1.11
Cancer chemopreventive activity and metabolism of isoliquiritigenin, a compound found in licorice. Cancer Prev Res (Phila) (2010) 1.11
Synthesis of benz[d]indeno[1,2-b]pyran-5,11-diones: versatile intermediates for the design and synthesis of topoisomerase I inhibitors. Bioorg Med Chem Lett (2006) 1.11
Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors. Bioorg Med Chem Lett (2004) 1.10
Structural basis for thermostability revealed through the identification and characterization of a highly thermostable phosphotriesterase-like lactonase from Geobacillus stearothermophilus. Arch Biochem Biophys (2009) 1.10
Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors. J Med Chem (2007) 1.10
Prospective type 1 and type 2 disulfides of Keap1 protein. Chem Res Toxicol (2008) 1.09
Trifolium pratense (red clover) exhibits estrogenic effects in vivo in ovariectomized Sprague-Dawley rats. J Nutr (2002) 1.09
Saliniketals A and B, bicyclic polyketides from the marine actinomycete Salinispora arenicola. J Nat Prod (2007) 1.09
Activity-guided isolation of cytotoxic constituents from the bark of Aglaia crassinervia collected in Indonesia. Bioorg Med Chem (2005) 1.09
Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) activation are dependent on the partial molar volume at position 151 of Keap1. Biochem J (2009) 1.09
Use of the in vivo hollow fiber assay in natural products anticancer drug discovery. J Nat Prod (2009) 1.09
Induction of quinone reductase as a primary screen for natural product anticarcinogens. Methods Enzymol (2004) 1.07
A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor. J Med Chem (2006) 1.07
Synthesis and biological evaluation of (+/-)-abyssinone II and its analogues as aromatase inhibitors for chemoprevention of breast cancer. J Med Chem (2007) 1.07
Cylindrocyclophanes with proteasome inhibitory activity from the Cyanobacterium Nostoc sp. J Nat Prod (2010) 1.07
Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization. J Med Chem (2007) 1.07
Cytotoxic and antimicrobial constituents of the bark of Diospyros maritima collected in two geographical locations in Indonesia. J Nat Prod (2004) 1.06
Cytotoxic withanolides from Acnistus arborescens. Phytochemistry (2002) 1.05
Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors. J Med Chem (2008) 1.05
MAIT recognition of a stimulatory bacterial antigen bound to MR1. J Immunol (2013) 1.04
An ab initio quantum mechanics calculation that correlates with ligand orientation and DNA cleavage site selectivity in camptothecin-DNA-topoisomerase I ternary cleavage complexes. J Am Chem Soc (2005) 1.04
Diastolic dysfunction is associated with cardiac fibrosis in the senescence-accelerated mouse. Am J Physiol Heart Circ Physiol (2011) 1.03
Sulforaphane prevents mouse skin tumorigenesis during the stage of promotion. Cancer Lett (2005) 1.02
Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors. Bioorg Med Chem Lett (2007) 1.02
A structure-based model of the reaction catalyzed by lumazine synthase from Aquifex aeolicus. J Mol Biol (2003) 1.02
The binding orientation of a norindenoisoquinoline in the topoisomerase I-DNA cleavage complex is primarily governed by pi-pi stacking interactions. J Phys Chem B (2008) 1.02
Novel marine phenazines as potential cancer chemopreventive and anti-inflammatory agents. Mar Drugs (2012) 1.01
Bacillus anthracis o-succinylbenzoyl-CoA synthetase: reaction kinetics and a novel inhibitor mimicking its reaction intermediate. Biochemistry (2008) 1.01
Structural and functional analysis of two glutamate racemase isozymes from Bacillus anthracis and implications for inhibitor design. J Mol Biol (2007) 1.01